Navigation Links
Biosimilar Insulins and Insulin Analogues Stand to Erode $6.1 Billion in Brand Sales in the U.S. and Europe by 2018
Date:10/14/2009

WALTHAM, Mass., Oct. 14 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that biosimilar insulins and insulin analogues stand to erode $6.1 billion in brand sales in the U.S. and Europe (France, Germany, Italy, Spain and U.K.) by 2018, saving healthcare systems $3.8 billion in the process.

As insulins are relatively easy to develop and manufacture, the new special report entitled Biosimilars: ESAs, Insulins, and Human Growth Hormones, predicts that a number of competing long-acting biosimilar insulins, which are typically injected once or twice daily, will enter the market during the 2008-2018 study period. Based on differences in revenue and upon patent expiry, Sanofi-Aventis' Lantus presents a greater opportunity for manufacturers of biosimilars than Novo-Nordisk's Levemir.

"Our survey data suggests that most endocrinologists expect to begin prescribing biosimilars within a year after they launch. Although endocrinologists will require a fair amount of clinical data before they will be comfortable prescribing biosimilars, they have fewer reservations about using biosimilar insulins (used in patients with diabetes) than they do for biosimilar human growth hormones (used in patients with human growth hormone deficiency)," stated MaryEllen Klusacek, Ph.D., analyst at Decision Resources.

The report also finds that although surveyed nephrologists have an overall conservative attitude towards biosimilar use, they are not completely opposed to prescribing a biosimilar for an indication in which it has been approved, but not clinically studied. Based on EMEA guidelines and proposed legislation in the United States, biosimilars will be labeled for each indication for which the reference product is labeled, even if the biosimilar is only clinically studied in one indication. For example, while Johnson & Johnson's Procrit/Eprex is approved for and used in the treatment of chronic renal failure and chemotherapy induced anemia, its biosimilar may only be studied in chemotherapy induced anemia, yet get approved for all of the indications that Procrit/Eprex is approved for.

"In order to head off competition from biosimilars that need additional validation, makers of branded biologics should create marketing campaigns focusing on their agents' proven safety and efficacy," added Dr. Klusacek.

About the Report

In 2009, Decision Resources expands the scope and analysis of its biosimilars product line to include oncology, immune and infectious disease and endocrinology/nephrology in three separate reports. The new report series covers 22 key biologic brands from eight biologic classes and include surveys of 456 U.S. and European physicians and 41 managed care organization pharmacy and medical directors.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                    Decision Resources, Inc.
    Gisselle Morales                      Elizabeth Marshall
    781-296-2691                          781-296-2563
    gmorales@dresources.com               emarshall@dresources.com

SOURCE Decision Resources


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Neutropenia: Biosimilar Product from India Moves One Step Closer to European Market
2. Oramed Pharmaceuticals Announces Launch of Phase 2B Clinical Trials in South Africa of its Oral Insulin Capsule
3. Oramed Pharmaceuticals to Present Oral Insulin Phase 2A Trial Results at the Upcoming Annual Meeting of the ADA (June 5-9, New Orleans, LA)
4. Oramed Pharmaceuticals Completes Proof of Concept Study of Insulin Suppository
5. Epidemics of Both Type 1 Diabetes (Insulin Dependent) and Type 2 Diabetes (Obesity Related) Are Linked to Immunization
6. FDA Approves Rapid-Acting Insulin Apidra(R) for Treatment of Children with Diabetes
7. Oramed Pharmaceuticals Launches Phase 1A Trials of its Insulin Suppository
8. Oramed Pharmaceuticals Commences Phase 2A Trials of its Oral Insulin Capsule on Type 1 Diabetics
9. MannKind Reports Positive Data from a Phase 3 Clinical Study of Technosphere Insulin in Type 1 Diabetes
10. Modified Insulin Most Effective For Controlling Post-Meal Blood Sugar Levels
11. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... , United Kingdom and  BOSTON , March ... provider Linguamatics today announced a partnership ... . The agreement allows pharmaceutical companies to extract ... I2E text mining technology. ... 18 of the top 20 global pharmaceutical companies. ...
(Date:3/28/2017)... Calif. , March 28, 2017  AcelRx ... focused on the development and commercialization of innovative ... announced that the European Medicines Agency (EMA) has ... tablet, 30 mcg) Marketing Authorisation Application (MAA) has ... the MAA is underway. The MAA for ARX-04 ...
(Date:3/28/2017)... -- The global flow cytometry market ... 2025, according to a new study by Grand View ... cancer is expected to upsurge the demand for flow ... years. In addition, higher number of physicians is inclined ... therapy, due to adverse effects caused by chemotherapy & ...
Breaking Medicine Technology:
(Date:3/28/2017)... ... 28, 2017 , ... Revolution for Truth has organized the ... parental rights and civil liberties, and to restore transparency within government agencies responsible ... with a press conference taking place Friday morning calling on President Trump to ...
(Date:3/28/2017)... ... ... Dr. Isabella Wentz, PharmD, FASCP, one of the leading thyroid experts of ... Dr. Wentz talked about journey and research recently on a blog and discussed some ... only solution to deal with thyroid disease. , Dr. Wentz completed her graduation ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... software and services, is proud to announce it has joined the National Association ... representing the interests of chronically ill, disabled, and dying Americans of all ages ...
(Date:3/28/2017)... Pittsburgh, PA (PRWEB) , ... March 28, 2017 ... ... built for and by physicians, announced today the launch of a free, public-facing ... The Via Cost Analyzer (VCA) was developed to provide comparative information to patients, ...
(Date:3/28/2017)... ... March 28, 2017 , ... Z-Medica, LLC, ... of Pittsburgh Medical Center (UPMC) will acquire QuikClot® Bleeding Control Kits® (BCK) to ... developed in association with efforts by the American College of Surgeons, U.S. Department ...
Breaking Medicine News(10 mins):